Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Distinguishing methylation levels in complex biological samples

a biological sample and complex technology, applied in the field of methylation pattern determination in genomic dna, can solve the problems of compromising the accuracy and affordability of currently available techniques, affecting the development of methylation detection techniques into robust and cost efficient screening tools, and often using cumbersome and expensive purification techniques to purify genomic samples

Pending Publication Date: 2022-06-02
ILLUMINA INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Several technical challenges hinder development of methylation detection techniques into a robust and cost efficient screening tool.
For example, the accuracy and affordability of currently available techniques can be compromised by impurities in samples that are to be tested.
As a result, cumbersome and expensive purification techniques are often employed to purify a genomic sample from background nucleic acids.
Depending upon the depth of the tissue in the body of an individual, biopsy can require unpleasant and risky harvesting procedures such as needle biopsy, endoscopy, bronchoscopy, colonoscopy or surgery.
However, circulating tumor DNA is typically present in low quantities and in a background of a relatively large quantity of non-tumor DNA.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Distinguishing methylation levels in complex biological samples
  • Distinguishing methylation levels in complex biological samples
  • Distinguishing methylation levels in complex biological samples

Examples

Experimental program
Comparison scheme
Effect test

example i

Analytical Sensitivity of ctDNA Methylation-Based Cancer Detection Using Aggregate Normalized Coverage-Weighted Methylation Differences

[0154]This example describes a highly sensitive assay for detecting methylation in circulating tumor DNA (ctDNA). Aberrant DNA methylation is a widespread phenomenon in cancer and may be among the earliest changes to occur during oncogenesis. The assay described in this example can be useful for cancer screening.

[0155]The general approach applied here includes targeted methylation sequencing for multiple CpG sites affected in cancer.

[0156]Technical challenges addressed by the approach include providing ultra-high sensitivity and specificity that benefits screening applications, providing a protocol for targeted methyl-seq from low input ctDNA, and providing bioinformatics algorithms for analysis of methylation levels across a large number of targeted sites.

Targeted Capture Probe Design

[0157]Two targeted methylation panels were developed. The Pan-Canc...

example ii

Analytical Sensitivity of ctDNA Methylation-Based Cancer Detection Using Coverage-Weighted Methylation Scores

[0171]This example describes an alternative highly sensitive assay for detecting methylation in circulating tumor DNA (ctDNA). The assay described in this example also can be useful for cancer screening, monitoring disease progression, or evaluating a patient's response to a therapeutic treatment.

Targeted Capture Probe Design

[0172]For this study, the two targeted methylation panels described in Example I were pooled together. The Pan-Cancer Panel targets 9,921 affected CpG sites in 20 major cancer types as selected from The Cancer Genome Atlas Database. The CpG sites included in the Pan-Cancer Panel are listed in Table I. The CRC Panel targets 1,162 affected CpG sites in colorectal cancer. The CpG sites included in the CRC Panel are listed in Table II. The combined CpG sites listed in Table I and Table II refer to Genome Build 37.

[0173]The probe sequences for the CpG sites we...

example iii

Clinical Performance of ctDNA Methylation-Based Cancer Detection Using Normalized Coverage-Weighted Methylation Score Differences

[0187]This example evaluates clinical sensitivity and specificity of the methylation-based cancer detection in circulating tumor DNA (ctDNA) using normalized coverage weighted methylation score differences. As noted above, the assay described in this example can be useful for cancer screening, monitoring disease progression, or evaluating a patient's response to a therapeutic treatment.

Targeted Capture Probe Design

[0188]For this study, the two targeted methylation panels described in Example I were pooled together. The Pan-Cancer Panel targets 9,921 affected CpG sites in 20 major cancer types as selected from The Cancer Genome Atlas Database. The CpG sites included in the Pan-Cancer Panel are listed in Table I. The CRC Panel targets 1,162 affected CpG sites in colorectal cancer. The CpG sites included in the CRC Panel are listed in Table II. The combined C...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein is a method for distinguishing an aberrant methylation level for DNA from a first cell type, including steps of (a) providing a test data set that includes (i) methylation states for a plurality of sites from test genomic DNA from at least one test organism, and (ii) coverage at each of the sites for detection of the methylation states; (b) providing methylation states for the plurality of sites in reference genomic DNA from one or more reference individual organisms, (c) determining, for each of the sites, the methylation difference between the test genomic DNA and the reference genomic DNA, thereby providing a normalized methylation difference for each site; and (d) weighting the normalized methylation difference for each site by the coverage at each of the sites, thereby determining an aggregate coverage-weighted normalized methylation difference score. Also provided herein are sensitive methods for using genomic DNA methylation levels to distinguish cancer cells from normal cells and to classify different cancer types according to their tissues of origin.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application claims the benefit of U.S. Provisional Application Ser. No. 62 / 401,591, filed Sep. 29, 2016, and U.S. Provisional Application Ser. No. 62 / 268,961, filed Dec. 17, 2015, each of which is incorporated by reference herein.BACKGROUND[0002]The present disclosure relates to determination of methylation patterns in genomic DNA. Specific embodiments relate to prediction, diagnosis, prognosis and monitoring of various conditions based on genomic methylation patterns.[0003]Changes in cellular genetic information, such as mutations in gene sequences which can affect gene expression and / or protein sequence, are associated with many diseases and conditions. However, changes can also occur to genes that affect gene expression; changes caused by mechanisms other than genetic mutations. Epigenetics is the study of changes in gene expression caused by mechanisms other than changes in the underlying DNA sequence, the methylation of DNA bein...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C12Q1/6886G16B40/00G16B99/00G16B25/10G16B20/10G16H50/30
CPCC12Q1/6886G16B40/00G16B99/00C12Q2600/154G16B20/10G16H50/30G16B25/10C12Q1/6881Y02A90/10
Inventor TOUNG, JONATHANLIU, LISHEN, MIN-JUIZHANG, RUOYU
Owner ILLUMINA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products